Suzhou, China · Founded 2017 · Privately Held (backing)
Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. Accro Bioscience is based in Suzhou, China and was founded in 2017. Its last reported valuation was $161 million in Jan 2022. It has raised $62 million.
Last reported valuation
$161.0M
Oct 2026
Priced at
—
Total raised
$62.0M
Last round
—
Cap table — not yet on record
Accro Bioscience's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Accro Bioscience with a free account
·Watch Accro Bioscience: the Monday email on marks, rounds and moves
